Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01788566 · ClinicalTrials.gov registry record · Phase 2
A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT01788566 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 61 participants.
The verdict
NCT01788566, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study is to see how participants with late stage lung cancer do on gemcitabine-cisplatin chemotherapy plus necitumumab. The study will also see how safe the drugs are in combination and to see how long the medicine stays in the body. The study will last approximately 2 years.
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Necitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01788566
The ClinicalTrials.gov registry entry for NCT01788566 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT01788566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01788566 about?
NCT01788566 is a clinical study titled "A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer". The purpose of this study is to see how participants with late stage lung cancer do on gemcitabine-cisplatin chemotherapy plus necitumumab. The study will also see how safe the drugs are in combination and to see how long the medicine stays in the body. The study will last approximately 2 years.
What is the current status of trial NCT01788566?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2013-03. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01788566?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Necitumumab (DRUG).
Who is sponsoring clinical trial NCT01788566?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.